ponasterone a has been researched along with camptothecin in 1 studies
| Studies (ponasterone a) | Trials (ponasterone a) | Recent Studies (post-2010) (ponasterone a) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 162 | 0 | 24 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | ponasterone a (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, GQ; Fliegauf, M; Lu, Y; Lübbert, M; Song, MG; Xu, YB; Yuan, TT | 1 |
1 other study(ies) available for ponasterone a and camptothecin
| Article | Year |
|---|---|
Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis.
Topics: Antibodies, Monoclonal; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Cycloheximide; Ecdysterone; fas Receptor; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Oncogene Proteins, Fusion; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Sensitivity and Specificity; Time Factors; Ultraviolet Rays | 2006 |